For now, they also play a critical and unique role for people who have become resistant to a first or second line protease inhibitor regimen. Just which strategy results in the longest possible life is unclear and there are no data to guide this decision. There is logic, if not data, to support all these choices. Yet each has different consequences later on down the line. Please refer to the Drug ID Chart for assistance.
People struggling with lipodystrophy problems face similar, uncharted courses of action.
Another strategy question looms over the fundamental issue of when to start therapy in the first place. Knowing what we do today, a reasonable case can be made for delaying therapy somewhat to avoid starting people on the cycle of potential side effects and drug resistance any earlier than necessary. In truth, the actual data from 1996 never recommended treatment for all HIV-infected people, nor did any other guideline. Yet many physicians interpreted the words of researchers to suggest exactly that. That leads to debate about whether there should be gender differences in deciding when to start therapy.